Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · mng-umap@100

MNG428

—

a0515a0b-c7f8-5a75-8edf-66820d33179c

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
—

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • OXIDATIVE_PHOSPHORYLATION+0.426
  • PANCREAS_BETA_CELLS+0.357
  • KRAS_SIGNALING_DN+0.305
  • ADIPOGENESIS+0.214
  • ESTROGEN_RESPONSE_LATE+0.212
  • INFLAMMATORY_RESPONSE+0.179
  • HEDGEHOG_SIGNALING+0.173
  • BILE_ACID_METABOLISM+0.152
  • INTERFERON_ALPHA_RESPONSE+0.152
  • KRAS_SIGNALING_UP+0.151

Top 10 suppressed

  • MYC_TARGETS_V1-0.486
  • G2M_CHECKPOINT-0.463
  • E2F_TARGETS-0.456
  • PROTEIN_SECRETION-0.399
  • MITOTIC_SPINDLE-0.355
  • DNA_REPAIR-0.343
  • EPITHELIAL_MESENCHYMAL_TRANSITION-0.246
  • UNFOLDED_PROTEIN_RESPONSE-0.206
  • APOPTOSIS-0.195
  • UV_RESPONSE_DN-0.195

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

2 twins match this tumor's tissue · 8 come from a different tissue of origin ← cross-tissue dominant

#SampleCancer typeSubtypecos similarity
1SJEPD001542_D1.RNA-Seq
medullo-epn-umap@date-based
EPNSupratentorial EPN0.786
2SRR1333767
brain-umap@2
GTEX—0.763
3TCGA-91-A4BD-01A-11R-A24H-07
lung-landscapes@6
—cohortA10.758
4SRR1399092
brain-umap@2
GTEX—0.751
5MDT-AP-0813
medullo-epn-umap@date-based
MedMedulloblastoma0.742
6TCGA-50-6597-01A-11R-1858-07
lung-landscapes@6
—cohortA10.742
7MDT-AP-2579
medullo-epn-umap@date-based
MedMedulloblastoma0.735
8MDT-AP-2378
medullo-epn-umap@date-based
MedMedulloblastoma0.734
9BS_VMMJYN8Z
brain-umap@2
Ganglioglioma—0.733
10ERR2598267
medullo-epn-umap@date-based
fetalfetal0.731

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 21 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
OXIDATIVE_PHOSPHORYLATION0.426Remibrutinib— uncovered
PANCREAS_BETA_CELLS0.357Cobimetinib— uncovered
KRAS_SIGNALING_DN0.305Remibrutinib— uncovered
ADIPOGENESIS0.214Inavolisib— uncovered
ESTROGEN_RESPONSE_LATE0.212Idelalisib— uncovered
INFLAMMATORY_RESPONSE0.179Idelalisib— uncovered
HEDGEHOG_SIGNALING0.173Inavolisib— uncovered
BILE_ACID_METABOLISM0.152Inavolisib— uncovered
INTERFERON_ALPHA_RESPONSE0.152Inavolisib— uncovered
KRAS_SIGNALING_UP0.151Inavolisib— uncovered
ESTROGEN_RESPONSE_EARLY0.142Inavolisib— uncovered
INTERFERON_GAMMA_RESPONSE0.142Idelalisib— uncovered
XENOBIOTIC_METABOLISM0.140Inavolisib— uncovered
ALLOGRAFT_REJECTION0.126Idelalisib— uncovered
IL6_JAK_STAT3_SIGNALING0.115Inavolisib— uncovered
APICAL_SURFACE0.099Temsirolimus— uncovered
SPERMATOGENESIS0.087Inavolisib— uncovered
FATTY_ACID_METABOLISM0.060Inavolisib— uncovered
APICAL_JUNCTION0.032Inavolisib— uncovered
PI3K_AKT_MTOR_SIGNALING0.017Inavolisib— uncovered